Under construction – not a live service
Sign in
Taking people in SwedenNo phase

Contactless skin scanners for blood flow in type 1 diabetes

Tests two contactless optical devices measuring skin blood flow in adults with type 1 diabetes.

Plain-language title generated from the registry record
Registry title: The MIND Study - Microangiopathy IN Diabetes

Key facts

Where
Stockholm, SwedenSee the site

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 1 diabetes, from no complications to severe ones, and healthy controls. It tests two contactless devices that measure blood flow in the skin.

Age
18 to 45 years. Up to 60 years in phase 1 if too few people can be found.
Sex
All sexes can join.
Disease stage
Type 1 diabetes. Phase 1: severe complications of the small blood vessels, such as proliferative retinopathy, macroalbuminuria, kidney failure of at least CKD-class 3B and severe neuropathy, with or without foot ulcers. Phase 2: no, mild or moderate complications.

Main reasons for not taking part

  • Cannot understand the patient information because of cognitive problems or language barriers
  • Ongoing acute infection or inflammatory condition
  • Pregnant or breastfeeding women
  • Damaged or scarred skin in the areas where the devices are used

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

Source: NCT06989190, who can take part

Where in Sweden

  • VO Medicinska Specialiteter, Danderyd HospitalStockholm, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
HJN Sverige AB/Neko Health
Trial code
NCT06989190
Record updated
25 May 2025
Original description
This clinical investigation will evaluate two contactless optical devices based on spatial frequency domain and laser speckle technology for quantification of the skin micro-circulation in patients with diabetes mellitus type 1.Read full original descriptionShow less

The MIND Study - Microangiopathy IN Diabetes

This clinical investigation will evaluate two contactless optical devices based on spatial frequency domain and laser speckle technology for quantification of the skin micro-circulation in patients with diabetes mellitus type 1.

Inclusion: Severe type 1 diabetes (microangiopathy / diabetic feet), severe angiopathy defined as proliferative retinopathy, macroalbuminuria, and kidney failure with at least CKD-class 3B and severe neuropathy with or without foot ulcers; Age range: primarily 18-45 years, if not sufficient number of subjects can be found, then 18-60 years span is considered; Phase 2: Scale of severity. In phase 2, patients are included with a broad range of severity levels. Patients with diabetes type 1 will be included; Age range: 18-45 years (younger patients are targeted for focus on microvascular complications, rather than age-related cardiovascular disease); Patient with no microangiopathy, except for simplex or background retinopathy, which is in an early and reversible state (group a), 100 patients; Patient with mild microangiopathy, mild-moderate non-proliferative retinopathy and/or microalbuminuria and/or early signs of neuropathy (group b), 100 patients; Patient with moderate microangiopathy. moderate non-proliferative retinopathy or proliferative retinopathy, macroalbuminuria or kidney failure (defined as estimated glomerular filtration rate <60 mL/min/1.73 m2 body surface) up to CKD-class 3A, and manifest neuropathy, (group c), 50 patients; Healthy controls:; Healthy control matched to the type 1 diabetes patients in age and gender, with no known risk of increased cardiovascular disease.

Exclusion: Patients unable to understand patient information due to cognitive impairment; Ongoing acute infection or inflammatory condition; Patients unable to understand patient information due to language barriers; Pregnant or breastfeeding women; Patients with damaged and/or scarred tissue in the areas of interest for the investigational or comparator devices.

Phase 1: Severe Diabetic Complications (50 patients).

ClinicalTrials.gov NCT06989190